Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$9.42 USD

9.42
363,633

+0.03 (0.32%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $9.42 0.00 (0.00%) 7:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus

by Zacks Equity Research

Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.

Kinjel Shah headshot

Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More

by Kinjel Shah

Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.

Zacks Equity Research

Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View

by Zacks Equity Research

Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.

Zacks Equity Research

Ultragenyx (RARE) Q1 Loss Narrows Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows

Zacks Equity Research

Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline

by Zacks Equity Research

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Prothena (PRTA) Stock Jumps 16.8%: Will It Continue to Soar?

by Zacks Equity Research

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Why Is Prothena (PRTA) Up 46.8% Since Last Earnings Report?

by Zacks Equity Research

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.

Zacks Equity Research

Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of 7.23% and 80.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Prothena (PRTA) Q4 Earnings Expected to Decline

by Zacks Equity Research

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.